Sign In
Home
About
Main Menu
Overview
Leadership Board
Program Partners
Affiliates
News Center
Contact
Advocacy
Main Menu
Featured
Insights & POV
Roundtables
Reports
Knowledge Center
Featured
Events
Industry News
Transform Tech TV
Sign In
Edit Fact
Text
I'll call back later http://xhamster-porn.in.net/ xhamster Patients who received Abraxane in combination with the chemotherapy agent gemcitabine had a median overall survival of 8.5 months, compared with 6.7 months for patients who received standard therapy of gemcitabine alone. The result was deemed to be statistically significant.
Publication
Url
Actions
Delete
List Facts